AAPS PharmSciTech

, Volume 2, Issue 3, pp 6–14 | Cite as

Long-term release of clodronate from biodegradable microspheres

  • Paola Perugini
  • Ida Genta
  • Bice Conti
  • Tiziana Modena
  • Franca Pavanetto
Article

Abstract

This paper describes the formulation of a biodegradable microparticulate drug delivery system containing clodronate, a bisphosphonate intended for the treatment of bone diseases. Microspheres were prepared with several poly(D,L-lactide-co-glycolide) (PLGA) copolymers of various molecular weights and molar compositions and 1 poly(D,L-lactide) (PDLLA) homopolymer by a water-in-oil-in-water (w/o/w) double emulsion solvent evaporation procedure. Critical process parameters and formulation variables (ie, addition of stabilizing agents) were evaluated for their effect on drug encapsulation efficiency and clodronate release rate from microparticles Well-formed clodronate-loaded microspheres were obtained for all polymers by selecting suitable process parameters (inner water/oil volume ratio 1∶16, temperature-raising rate in the solvent evaporation step 1°C/min, 2% wt/vol NaCl in the external aqueous phase). Good yields were obtained in all batches of clodronate microspheres (above 60%); drug encapsulation efficiencies ranged between 49% and 75% depending on the polymer used. Clodronate release from all copolymer microspheres was completed in about 48 hours, while those from PDLLA microspheres required about 20 days. The change of microsphere composition by adding a surfactant such as Span 20 or a viscosing agent such as carboxymethylcellulose extended the long-term release up to 3 months. Clodronate was successfully entrapped in PLGA and PDLLA microspheres, and drug release could be modulated from 48 hours up to 3 months by suitable selection of polymer, composition, additives, and manufacturing conditions.

KeyWords

PLGA microspheres solvent evaporation method long-term release Clodronate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    PD Delmas, PJ Meunier. The management of Paget's disease of bone. New Engl J Med. 1997;336:558–566.CrossRefGoogle Scholar
  2. 2.
    JA Kanis. Rationale for the use of bisphosphonates in breast cancer. Acta Oncol. 1996;35(Suppl 5):61–67.CrossRefGoogle Scholar
  3. 3.
    H Fleisch. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med. 1997;29:55–62.CrossRefGoogle Scholar
  4. 4.
    H Shinoda, G Adamek, R Felix, H Fleish, R Schenk. Structure-activity relationship of various bisphosphonates. Cale Tissue Int. 1983;35:87–99.CrossRefGoogle Scholar
  5. 5.
    GJ Yakatan, WJ Poynor, RL Talbert, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther. 1982;31:402–410.CrossRefGoogle Scholar
  6. 6.
    L Lauren, T Osterman, T Karhi. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats. Pharmacol Toxicol. 1991;69:365–368.CrossRefGoogle Scholar
  7. 7.
    M Rossini, D Gatti, D Gerardi, N Zamberlan, V Braga, S Adami. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone. 1999;24:125–129.CrossRefGoogle Scholar
  8. 8.
    A Ezra, G Golomb. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Del Rev. 2000;42:175–195.CrossRefGoogle Scholar
  9. 9.
    S Patashnik, L Rabinovich, G Golomb. Preparation and evaluation of chitosan microspheres containing bisphosphonates. J Drug Targ. 1997;4:371–380.Google Scholar
  10. 10.
    H Okada, H Toguchi. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst. 1995;12:1–99.Google Scholar
  11. 11.
    S Gogolewski, P Mainil-Varlet. Effect of thermal treatment on sterility, molecular and mechanical properties of various polylactides. Biomaterials. 1997;18:251–255.CrossRefGoogle Scholar
  12. 12.
    S Cohen, T Yoshioka, M Lucarelli, LH Hwang, R Langer. Controlled delivery systems for proteins based on poly(lactic glycolic acid) microspheres. Pharm Res. 1991;8:713–720.CrossRefGoogle Scholar
  13. 13.
    D Ostovic, C Stelmach, B Hulshizer. Formation of a chromophoric complex between alendronate and copper (II) ions. Pharm Res. 1993;10:470–472.CrossRefGoogle Scholar
  14. 14.
    T Uchida, K Yoshida, S Goto. Preparation and characterization of polylactic acid microspheres containing water-soluble dyes using a novel w/o/w emulsion solvent evaporation method. J Microencapsul. 1996;13:219–228.CrossRefGoogle Scholar
  15. 15.
    Y Ogawa, M Yamamoto, H Okada, T Yashiki, T Shimamoto. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly (lactic glycolic) acid. Chem Pharm Bull. 1988;36:1095–1103.Google Scholar
  16. 16.
    RW Baker, Biodegradable systems. In: R Baker, ed.Controlled release of biologically active agents. New York: John Wiley & Sons; 1987:84–131Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2001

Authors and Affiliations

  • Paola Perugini
    • 1
  • Ida Genta
    • 1
  • Bice Conti
    • 1
  • Tiziana Modena
    • 1
  • Franca Pavanetto
    • 1
  1. 1.Department of Pharmaceutical ChemistryUniversity of PaviaPaviaItaly

Personalised recommendations